Episurf Medical appoints Rosemary Cunningham Thomas as new

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Episurf Medical appoints Rosemary Cunningham Thomas as new CEO

Stockholm, 2015-06-09 08:30 CEST (GLOBE NEWSWIRE) --  

Rosemary Cunningham Thomas has broad experience leading companies through critical growth stages to become industry-leading players with good profitability. She has been the CEO of UK-based ToHealth Ltd., interim CEO of FreeHand 2010 Ltd. and European President & General Manager of Galil Medical. Prior to that, she was Sales and Marketing Director for CR Bard, Inc., listed on the New York Stock Exchange. Rosemary has also held several key positions at Smiths Industries Med Systems (now Smiths Medical) listed on the FTSE 100, as Speciality Business Unit Manager, Sales and Marketing Director and Clinical Development Specialist responsible for commercial partnerships. Rosemary has an educational background in pharmacy and economics.

"We are delighted to welcome Rosemary Cunningham Thomas as the new CEO of Episurf Medical. The company is in a growth phase with a strong focus on sales and marketing in Europe and eventually North America. Rosemary's experience in leading organizations to profitability and generating growth in international markets will be valuable to Episurfs continued development", comments Saeid Esmaeilzadeh, Chairman of Episurf Medical AB.

"Episurf Medical has a very interesting platform technology addressing a growing global market. What attracted me is the company's innovative technology, broad patent portfolio and unique know how in personalized treatments for people with joint problems. I’m very glad to be joining Episurf and believe that my experience has well equipped me to lead the company towards becoming an industry leader and a pioneer in the field of patient specific orthopedic treatments’’, says Rosemary Cunningham Thomas.

For more information, please contact: Saeid Esmaeilzadeh, Chairman of Episurf Medical AB Tel: +46-707187061 E-post: ir@episurf.com  

About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are in development for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system will enable implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.  

Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com . The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 127

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 170

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 197

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 150

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 303

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 309

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 148

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 108

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 268

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading

Top 5 Most Recently Viewed Articles

Healthcare Realty Trust's Q4 Highlights and Dividend Update

Updated Category News Views 112

Healthcare Realty Trust Quarterly Results Overview Healthcare Realty Trust Incorporated (NYSE: HR) has reported its fourth quarter results for the year 2024, highlighting significant developments in its operations and financial performance. The company recorded a net (loss) income attributable to common stockholders of $(106.8) million, or $(0.31) per diluted share,...

Continue Reading
BGL's Strategic Move: Selling Western Botanicals to Riverside

Updated Category News Views 322

Brown Gibbons Lang & Company (BGL) has just sealed the deal on a significant sale—Western Botanicals, a prominent player in the Vitamins, Minerals, and Supplements (VMS) contract development and manufacturing space, is headed to The Riverside Company. Now this isn’t just another corporate shuffle; it's BGL’s third foray into the CDMO subsector and marks their fourth...

Continue Reading
High Arctic Energy Services Reports Second Quarter 2025 Success

Updated Category News Views 225

High Arctic Energy Services Reports Strong Second Quarter Results High Arctic Energy Services Inc. (TSX: HWO), a noted energy services provider, has recently shared its financial results for the second quarter of 2025, highlighting a continued commitment to operational excellence amid challenging market conditions. 2025 Second Quarter Performance Overview The company...

Continue Reading
DXC Technology Investors Notified of Securities Class Action

Updated Category News Views 45

DXC Technology Class Action Notice for Shareholders The Gross Law Firm has released an important notice for shareholders of DXC Technology Company (NYSE: DXC). This notice is aimed at individuals who acquired shares during the specified class period. Shareholders are encouraged to reach out to the firm if they are interested in being considered for the role of lead...

Continue Reading
Manulife's $750M US Offering: Risky or Strategic?

Updated Category News Views 50

Manulife: Debuting $750M in Subordinated Notes When it comes to Manulife's latest move, it's all about the numbers. They've priced a U.S. public offering of a meaty $750 million in subordinated notes at an enticing 6.146% interest rate. That's no pocket change, folks, and it highlights a strategy or a gamble, depending on your view. But here's the kicker: these notes may...

Continue Reading